Clinical Trial Update: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trametinib combined with the Akt inhibitor GSK2141795 in relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GSK2141795 (GSK2141795)
• Trametinib (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2022-03-02